Clinical trials: Non-proliferative Diabetic Retinopathy
Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD) or non-proliferative diabetes retinopathy (NPDR).
- Conditions
- Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy, Healthy Volunteers
- Trial name
- NCT06487845
- Testing
- BAY3283142
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Non-proliferative Diabetic Retinopathy
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).
- Trial name
- NCT02388984
- Testing
- Compound danshen dripping pills
- Where
- 16 sites in China
- Volunteers
- 480 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Diabetic Retinopathy
Evaluation of RC28-E Injection in Diabetic Retinopathy
This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately…
- Trial name
- NCT04782128
- Testing
- RC28-E injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in…
- Trial name
- NEXUS (NCT07259928)
- Testing
- ANXV
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Annexin Pharmaceuticals AB
Diabetic Retinopathy
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
- Trial name
- NCT05409235
- Testing
- OTT166, Vehicle control
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 225 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Proliferative Diabetic Retinopathy
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
- Trial name
- NCT00170742
- Testing
- Octreotide, 30 mg i.m. LAR formulation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Novartis
Diabetic Macular Edema, Diabetic Retinopathy
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
- Trial name
- NCT06701721
- Testing
- THN391
- Where
- 10 sites in Australia, Georgia
- Volunteers
- 21 people
- Sponsor
- Therini Bio Pty Ltd
Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography…
- Trial name
- NEON-NPDR (NCT04722991)
- Testing
- Runcaciguat (BAY1101042)
- Where
- 55 sites in United States, Bulgaria and 12 more
- Volunteers
- 109 people
- Sponsor
- Bayer
Nonproliferative Diabetic Retinopathy
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy…
- Trial name
- TIME-2b (NCT03197870)
- Testing
- AKB-9778
- Where
- 53 sites in United States
- Volunteers
- 167 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period…
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema
- Trial name
- NCT06599684
- Testing
- INV-102
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Invirsa, Inc.
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Qlaris Bio, Inc.
Type2 Diabetes, Diabetic Retinopathy
Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy
This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.
- Trial name
- NCT05007262
- Testing
- Tangningtongluo tablets, Calcium dobesilate capsules
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.
- Trial name
- NCT00908778
- Testing
- Vitreosolve
- Where
- 5 sites in India, Mexico
- Volunteers
- 160 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR).
- Trial name
- NCT06770933
- Testing
- VX-01
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 100 people
- Sponsor
- Vantage Biosciences Ltd
Diabetic Retinopathy
Computer Detection of Diabetic Retinopathy Compared to Clinical Examination
The hypothesis is that computer detection of the severity of diabetic retinopathy including the presence of clinically significant macular edema is not inferior to the detection using a dilated eye examination by a…
- Trial name
- CDDR (NCT01625598)
- Testing
- Photography of the retina, Retinal photography
- Where
- 7 sites in United States
- Volunteers
- 600 people
- Sponsor
- Digital Diagnostics, Inc.
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.
- Trial name
- NCT00664183
- Testing
- Vitreosolve
- Where
- 17 sites in United States, India
- Volunteers
- 400 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00131144
- Testing
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- Novartis
Non-Proliferative Diabetic Retinopathy
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
The goal of this clinical trial is to learn if drug TNTL works to treat non-proliferative diabetic retinopathy in adults. It will also learn about the safety of drug TNTL. The main questions it aims to answer are: 1.
- Trial name
- TNTL (NCT06817265)
- Testing
- TNTL, TNTL simulation preparation
- Where
- 30 sites in China
- Volunteers
- 360 people
- Sponsor
- Beletalent (Zhuhai) Pharmaceutical Co., Ltd